Nevan Charles Elam, Rezolute CEO (Softhale)
Another public biotech hops on the trial-win-to-stock-sale train, netting a nine-figure raise
After unveiling Phase II data that, according to Rezolute, “exceeded expectations” with a drug for congenital hyperinsulinism, the Silicon Valley-based biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.